Close
  Indian J Med Microbiol
 

Figure 2: PSA progression-free survival curves of the three PSA groups. (a) PSA progression-free survival rate in response to antiandrogen withdrawal among the three groups. Patients in the high PSA level group had significantly longer PSA progression-free survival than those in the low PSA level group (P = 0.047). (b) PSA progression-free survival rate in response to alternative antiandrogen therapy among the three groups. Patients with high PSA levels had significantly longer PSA progression-free survival (P = 0.049). PSA: prostate-specific antigen.

Figure 2: PSA progression-free survival curves of the three PSA groups. (<b>a</b>) PSA progression-free survival rate in response to antiandrogen withdrawal among the three groups. Patients in the high PSA level group had significantly longer PSA progression-free survival than those in the low PSA level group (<i>P</i> = 0.047). (<b>b</b>) PSA progression-free survival rate in response to alternative antiandrogen therapy among the three groups. Patients with high PSA levels had significantly longer PSA progression-free survival (<i>P</i> = 0.049). PSA: prostate-specific antigen.